Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iloprost, quantity: 10 microgram/ml - inhalation, conventional - excipient ingredients: trometamol; hydrochloric acid; ethanol; sodium chloride; water for injections - treatment of patients with primary pulmonary hypertension or secondary pulmonary hypertension due to connective tissue disease or drug-induced, in moderate or severe stages of the disease. in addition, treatment of moderate or severe secondary pulmonary hypertension due to chronic pulmonary thromboembolism, where surgery is not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - vardenafil hydrochloride trihydrate, quantity: 23.705 mg (equivalent: vardenafil, qty 20 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; macrogol 400; hypromellose; titanium dioxide; iron oxide yellow; iron oxide red - levitra is indicated for the treatment of erectile dysfunction in adult males (inability to achieve or maintain penile erection sufficient for satisfactory sexual performance). levitra is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; lactose monohydrate; hyprolose; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; propylene glycol; titanium dioxide; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; sodium lauryl sulfate; hyprolose; magnesium stearate; lactose monohydrate; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; crospovidone - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; propylene glycol; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; crospovidone; hyprolose; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium lauryl sulfate; hypromellose; titanium dioxide; crospovidone; propylene glycol; lactose monohydrate; iron oxide red; microcrystalline cellulose; iron oxide yellow; hyprolose - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 0.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; propylene glycol; crospovidone; titanium dioxide; hyprolose; lactose monohydrate; sodium lauryl sulfate - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - regorafenib, quantity: 40 mg - tablet - excipient ingredients: polyvinyl alcohol; croscarmellose sodium; iron oxide red; microcrystalline cellulose; povidone; purified talc; magnesium stearate; titanium dioxide; macrogol 3350; colloidal anhydrous silica; iron oxide yellow; lecithin - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine,- oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and, if ras wild type, an anti-egfr therapy.,stivarga is indicated for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumours (gist) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.,stivarga is indicated for the treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; macrogol 3350; magnesium stearate - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - sorafenib tosilate, quantity: 274 mg (equivalent: sorafenib, qty 200 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; titanium dioxide; hypromellose; microcrystalline cellulose; sodium lauryl sulfate; macrogol 3350; ferric oxide; magnesium stearate - hepatocellular carcinoma. nexavar is indicated for the treatment of patients with advanced hepatocellular carcinoma (hcc). renal cell carcinoma. nexavar is indicated for the treatment of patients with advanced renal cell carcinoma (rcc). differentiated thyroid carcinoma. nexavar is indicated for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine.